The Prognostic Value of Additional Copies of 1q21 in Multiple Myeloma Depends on the Primary Genetic Event

Overview

Journal Am J Hematol

Specialty Hematology

Date 2020 Sep 16

PMID 32936982

Citations 16

Authors

Maurus Locher

Michael Steurer

Emina Jukic

Markus A Keller

Friedrich Fresser

Carmen Ruepp

Ewald Woll

Irmgard Verdorfer

Gunther Gastl

Wolfgang Willenbacher

Roman Weger

David Nachbaur

Dominik Wolf

Eberhard Gunsilius

Johannes Zschocke

Normann Steiner

Affiliations

Soon will be listed here.

Abstract

Hyperdiploidy (HRD) and specific immunoglobulin heavy locus (IGH) translocations are primary chromosomal abnormalities (CA) in multiple myeloma (MM). In this retrospective study of 794 MM patients we aimed to investigate clinical features and common CA including gain(1q) in separate subgroups defined by primary CA. In the entire group, we confirmed that gain(1q) was associated with short time to next treatment and adverse overall survival (OS). The impact was worse for four or more copies of 1q21 as compared to three copies. However, in a subgroup of patients with clonal gain(11q) and without known primary IGH translocations (CG11q), already three copies of 1q21 were associated with a poor outcome; in the absence of gain(1q), patients in this subgroup had a remarkably long median OS of more than nine years. These cases were associated with HRD, coexpression of CD56 and CD117, male gender, and IgG subtype. In non-CG11q patients, four or more copies of 1q21 (but not three copies) had a significant adverse impact on outcome. Several associations with CA and clinical findings were observed for the defined subgroups. As an example, we found a predominance of early tetraploidy, plasma cell leukemia, and female gender in the t(14;16) subgroup. Our results underscore the importance of subgrouping in MM.

Citing Articles

Clinical and immunological characteristics of high-risk double-hit multiple myeloma.

Shang Y, Chen G, Liu L, Pan R, Li X, Shen H BMC Cancer. 2024; 24(1):1373.

PMID: 39523318 PMC: 11552351. DOI: 10.1186/s12885-024-13124-6.

Del(1p32) is an early and high-risk event in multiple myeloma patients with extraosseous disease.

Stork M, Ondrouskova E, Bohunova M, Boichuk I, Fric D, Adam Z Blood Cancer J. 2024; 14(1):146.

PMID: 39187485 PMC: 11347579. DOI: 10.1038/s41408-024-01131-6.

Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells.

DAgostino M, Rota-Scalabrini D, Belotti A, Bertamini L, Arigoni M, De Sabbata G Blood Cancer J. 2024; 14(1):94.

PMID: 38849344 PMC: 11161499. DOI: 10.1038/s41408-024-01075-x.

Molecular characterization stratifies VQ myeloma cells into two clusters with distinct risk signatures and drug responses.

Flietner E, Yu M, Poudel G, Veltri A, Zhou Y, Rajagopalan A Oncogene. 2023; 42(21):1751-1762.

PMID: 37031341 PMC: 10367583. DOI: 10.1038/s41388-023-02684-9.

Experts' consensus on the definition and management of high risk multiple myeloma.

Marcon C, Simeon V, Deias P, Facchin G, Corso A, Derudas D Front Oncol. 2023; 12:1096852.

PMID: 36755858 PMC: 9899889. DOI: 10.3389/fonc.2022.1096852.

References

Mikhael J, Dingli D, Roy V, Reeder C, Buadi F, Hayman S . Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc. 2013; 88(4):360-76. DOI: 10.1016/j.mayocp.2013.01.019. View

Pawlyn C, Cairns D, Kaiser M, Striha A, Jones J, Shah V . The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial. Leukemia. 2019; 34(2):604-612. PMC: 7214257. DOI: 10.1038/s41375-019-0595-5. View

Dutta A, Fink J, Grady J, Morgan G, Mullighan C, To L . Subclonal evolution in disease progression from MGUS/SMM to multiple myeloma is characterised by clonal stability. Leukemia. 2018; 33(2):457-468. PMC: 6365384. DOI: 10.1038/s41375-018-0206-x. View

Avet-Loiseau H, Attal M, Campion L, Caillot D, Hulin C, Marit G . Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. J Clin Oncol. 2012; 30(16):1949-52. DOI: 10.1200/JCO.2011.36.5726. View

Ross F, Avet-Loiseau H, Ameye G, Gutierrez N, Liebisch P, OConnor S . Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders. Haematologica. 2012; 97(8):1272-7. PMC: 3409827. DOI: 10.3324/haematol.2011.056176. View

Kumar S, Kimlinger T, Morice W . Immunophenotyping in multiple myeloma and related plasma cell disorders. Best Pract Res Clin Haematol. 2010; 23(3):433-51. PMC: 3005703. DOI: 10.1016/j.beha.2010.09.002. View

Weinhold N, Kirn D, Seckinger A, Hielscher T, Granzow M, Bertsch U . Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma. Haematologica. 2015; 101(3):e116-9. PMC: 4815741. DOI: 10.3324/haematol.2015.136929. View

Pozdnyakova O, Morgan E, Li B, Shahsafaei A, Dorfman D . Patterns of expression of CD56 and CD117 on neoplastic plasma cells and association with genetically distinct subtypes of plasma cell myeloma. Leuk Lymphoma. 2012; 53(10):1905-10. DOI: 10.3109/10428194.2012.676174. View

Shah V, Sherborne A, Walker B, Johnson D, Boyle E, Ellis S . Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients. Leukemia. 2017; 32(1):102-110. PMC: 5590713. DOI: 10.1038/leu.2017.179. View

10.

Kumar S, Rajkumar S . The multiple myelomas - current concepts in cytogenetic classification and therapy. Nat Rev Clin Oncol. 2018; 15(7):409-421. DOI: 10.1038/s41571-018-0018-y. View

11.

Schmidt T, Barwick B, Joseph N, Heffner L, Hofmeister C, Bernal L . Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone. Blood Cancer J. 2019; 9(12):94. PMC: 6877577. DOI: 10.1038/s41408-019-0254-0. View

12.

Hanamura I, Stewart J, Huang Y, Zhan F, Santra M, Sawyer J . Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell.... Blood. 2006; 108(5):1724-32. PMC: 1895503. DOI: 10.1182/blood-2006-03-009910. View

13.

Bergsagel P, Kuehl W . Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol. 2005; 23(26):6333-8. DOI: 10.1200/JCO.2005.05.021. View

14.

Narita T, Inagaki A, Kobayashi T, Kuroda Y, Fukushima T, Nezu M . t(14;16)-positive multiple myeloma shows negativity for CD56 expression and unfavorable outcome even in the era of novel drugs. Blood Cancer J. 2015; 5:e285. PMC: 4349263. DOI: 10.1038/bcj.2015.6. View

15.

Greipp P, San Miguel J, Durie B, Crowley J, Barlogie B, Blade J . International staging system for multiple myeloma. J Clin Oncol. 2005; 23(15):3412-20. DOI: 10.1200/JCO.2005.04.242. View

16.

Walker B, Mavrommatis K, Wardell C, Ashby T, Bauer M, Davies F . Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood. 2018; 132(6):587-597. PMC: 6097138. DOI: 10.1182/blood-2018-03-840132. View

17.

Walker B, Mavrommatis K, Wardell C, Ashby T, Bauer M, Davies F . A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. 2018; 33(1):159-170. PMC: 6326953. DOI: 10.1038/s41375-018-0196-8. View

18.

Bielski C, Zehir A, Penson A, Donoghue M, Chatila W, Armenia J . Genome doubling shapes the evolution and prognosis of advanced cancers. Nat Genet. 2018; 50(8):1189-1195. PMC: 6072608. DOI: 10.1038/s41588-018-0165-1. View

19.

Neben K, Lokhorst H, Jauch A, Bertsch U, Hielscher T, van der Holt B . Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood. 2011; 119(4):940-8. DOI: 10.1182/blood-2011-09-379164. View

20.

Boyd K, Ross F, Chiecchio L, Dagrada G, Konn Z, Tapper W . A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia. 2011; 26(2):349-55. PMC: 4545515. DOI: 10.1038/leu.2011.204. View